BRAF-targeted therapies: cost effective for metastatic melanoma?

    loading  Checking for direct PDF access through Ovid

Abstract

About 50% of melanomas exhibit a mutation in the BRAF oncogene (primarily V600E and V600K mutations), and new therapies targeting BRAFV600 mutations include vemurafenib, dabrafenib, and trametinib, although their availability may differ between countries. Cost-effectiveness analyses presented as posters at the 19th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) [Montreal, Canada; May 2014] provided somewhat variable findings with these agents in the USA, Canada and the UK.

Related Topics

    loading  Loading Related Articles